# US 2012/0251459 A1 · Specific inhibitors and active site probes for legumain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251459 A1
- Document ID: US20120251459A1
- Status: Published application
- Kind: A1
- Application number: 13/516,643
- Filed: 2010-12-17
- Published: 2012-10-04
- Earliest claimed: 2009-12-18
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Jiyoun Lee; Fangfang Yin; Matthew S. Bogyo; Laura E. Edgington
- Web page: https://patentgrep.com/patent/US20120251459A1

## CPC

- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/06086: {with the first amino acid being basic}
- C07K 5/06139: {with the first amino acid being heterocyclic}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compounds which specifically inhibit legumain, also known as asparaginyl endopeptidase are provided. The compounds have an epoxide or N-Michael acceptor warhead, and have an asparagine side chain attached to a nitrogen atom in the backbone adjacent the warhead. The compounds also preferably comprise a proline residue adjacent the asparagine, and the compound may also contain a third residue and/or a label for cellular or in vivo imaging of active legumain.

## Claims

### Claim 1

A compound for inhibiting legmain, having a formula according to either Formula I or Formula II below
wherein,
(a) R1 has the formula -linker-label, or -linker, where linker is lower alkyl, lower alkyl-aryl, or aryl; and label is a radiolabel or an optical label, said linker further optionally comprising a cell penetrating peptide;
(b) P3 is an amino acid side chain that is either leucine or a non-natural amino acid selected from the group consisting of (2furyl)alanine, (2thienyl)alanine, 4pyridylAla, 1amino1cyclohexane carboxylic acid, 1amino1cyclopentanecarboxylic acid, 2-Abz, 3Abz, 2Abu, 3amino3phenylpropionic acid, dehydroAbu, ACPC, Aib, AllylGly, Amb, Amc, Bip, Bpa, Cba, Cha, deltaLeu, deltaVal, Hyp, Igl, Inp, 1-Nal, 2-Nal, Nva, 4-nitroPhe, 4MethylPhe, 4Methyl-DPhe, Phe(pI), Phe4NH(Boc), hPhe, Phg, pip, Dpip, propargylglycine, Thz, Tic, Tle, 3-NitroTyr, Fmoc-L-neopentylglycine, Fmoc-pCl-L-Phe-OH, Fmoc-pBr-L-Phe-OH, Fmoc-4-amino-tetrahydropyran-4-carboxylic acid, Fmoc-L-Hol, Fmoc-Pip(Boc)-OH, Fmoc-L-styrylalanine, Fmoc-L-homoCha, Fmoc-L-Dab(Boc)-OH, Fmoc-L-Dapa(Boc)-OH, Fmoc-4-[2-(Boc-amino)ethoxy]-L-phenylalanine, and Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine;
(c) P2 is proline, or, in Formula I only, leucine or a non-natural amino acid as defined for P3;
(d) W has the formula of a C double bonded to its adjacent CH group or an epoxide group wherein W is C and an epoxide oxygen is bonded to it and an adjacent carbon; and
(e) R2 is selected from the group consisting of lower alkyl, aryl, and lower alkyl-aryl.

### Claim 2 (depends on 1)

A compound of claim 1 having the formula, according to Formula I

### Claim 3 (depends on 1, 2)

A compound of claim 1 or 2 wherein R1 is lower alkyl linked to a fluorescent dye.

### Claim 4 (depends on 3)

A compound of claim 3 wherein the fluorescent dye is Cy5.

### Claim 5 (depends on 2)

A compound of claim 2 wherein R1 is linked to a dye and R2 is ethyl.

### Claim 6 (depends on 1)

A compound of claim 1 wherein R1 is linked to a dye and R2 is ethyl.

### Claim 7 (depends on 1)

A compound of claim 1 according to formula I wherein W is a double bond and P2 is proline.

### Claim 8 (depends on 1, 2, 4, 5, 6)

A compound according to one of claim 1, 2, 4, 5 or 6 wherein R2 is one of ethyl, methyl, propyl or butyl.

### Claim 9

A method of specifically inhibiting legumain activity, comprising the step of contacting the legumain with a compound according to the formula
wherein
(a) R1 has the formula -linker-label, or -linker, where linker is lower alkyl, lower alkyl-aryl, or aryl, and label is a radiolabel or a fluorescent label, said linker further optionally comprising a cell penetrating peptide;
(b) P3 is an amino acid side chain that is either leucine or a non-natural amino acid selected from the group consisting of (2furyl)alanine, (2thienyl)alanine, 4pyridylAla, 1amino1cyclohexane carboxylic acid, 1amino1cyclopentanecarboxylic acid, 2-Abz, 3Abz, 2Abu, 3amino3phenylpropionic acid, dehydroAbu, ACPC, Aib, AllylGly, Amb, Amc, Bip, Bpa, Cba, Cha, deltaLeu, deltaVal, Hyp, Igl, Inp, 1-Nal, 2-Nal, Nva, 4-nitroPhe, 4MethylPhe, 4Methyl-DPhe, Phe(pI), Phe4NH(Boc), hPhe, Phg, pip, Dpip, propargylglycine, Thz, Tic, Tle, 3-NitroTyr, Fmoc-L-neopentylglycine, Fmoc-pCl-L-Phe-OH, Fmoc-pBr-L-Phe-OH, Fmoc-4-amino-tetrahydropyran-4-carboxylic acid, Fmoc-L-Hol, Fmoc-Pip(Boc)-OH, Fmoc-L-styrylalanine, Fmoc-L-homoCha, Fmoc-L-Dab(Boc)-OH, Fmoc-L-Dapa(Boc)-OH, Fmoc-4-[2-(Boc-amino)ethoxy]-L-phenylalanine, and Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine;
(c) P2 is proline, or, in Formula I only, proline or leucine or a non-natural amino acid as defined for P3;
(d) W has the formula of a double bond to its adjacent CH group or an epoxide group wherein W is C and an epoxide oxygen is bonded to it and an adjacent carbon; and
(e) R2 selected from the group consisting of lower alkyl, aryl, and lower alkyl-aryl.

### Claim 10 (depends on 8)

A method according to claim 8 wherein R1 comprises a lower alkyl or aryl group without a label.

### Claim 11 (depends on 9)

A method according to claim 9 wherein the compound is a compound having the formula:

### Claim 12 (depends on 9)

A method according to claim 9 wherein the compound is a compound having the formula:

### Claim 13 (depends on 12)

A method according to claim 12 wherein R1 and R3 comprise lower alkyl linkers having between three and twelve atoms, said linkers being linked to a label.

### Claim 14 (depends on 13)

A method according to claim 13 wherein R1 comprises a cell permeability peptide.

### Claim 15 (depends on 14)

A method according to claim 14 wherein R2 is one of ethyl, methyl, propyl or butyl.

### Claim 16

A method of imaging a tissue in an organism having active legumain in the tissue, comprising administering to the organism a compound according to the formula
wherein,
(a) R1 has the formula -linker-label, or -linker, where linker is lower alkyl, lower alkyl-aryl, or aryl, and label is a radiolabel or an optical label, said linker further optionally comprising a cell penetrating peptide;
(b) P3 is an amino acid side chain that is either leucine or a non-natural amino acid selected from the group consisting of (2furyl)alanine, (2-thienyl)alanine, 4pyridylAla, 1amino1cyclohexane carboxylic acid, 1amino1cyclopentanecarboxylic acid, 2-Abz, 3Abz, 2Abu, 3amino3phenylpropionic acid, dehydroAbu, ACPC, Aib, AllylGly, Amb, Amc, Bip, Bpa, Cba, Cha, deltaLeu, deltaVal, Hyp, Igl, Inp, 1-Nal, 2-Nal, Nva, 4-nitroPhe, 4MethylPhe, 4Methyl-DPhe, Phe(pI), Phe4NH(Boc), hPhe, Phg, pip, Dpip, propargylglycine, Thz, Tic, Tle, 3-NitroTyr, Fmoc-L-neopentylglycine, Fmoc-pCl-L-Phe-OH, Fmoc-pBr-L-Phe-OH, Fmoc-4-amino-tetrahydropyran-4-carboxylic acid, Fmoc-L-Hol, Fmoc-Pip(Boc)-OH, Fmoc-L-styrylalanine, Fmoc-L-homoCha, Fmoc-L-Dab(Boc)-OH, Fmoc-L-Dapa(Boc)-OH, Fmoc-4-[2-(Boc-amino)ethoxy]-L-phenylalanine, and Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine;
(c) P2 is proline, or, in Formula I only, proline or leucine or a non-natural amino acid as defined for P3;
(d) W has the formula of C double bond to its adjacent CH group or an epoxide group wherein W is C and an epoxide oxygen is bonded to it and an adjacent carbon; and
(e) R2 is selected from the group consisting of lower alkyl, aryl, and lower alkyl-aryl.

### Claim 17 (depends on 16)

A method according to claim 16 wherein R1 is a linker to a fluorescent dye.

### Claim 18 (depends on 16)

A method according to claim 16 wherein said tissue comprises a tumor preferentially labeled by said compound.

### Claim 19 (depends on 1)

A composition suitable for administration in vivo, for imaging legumain activity in tissue, comprising a compound according to claim 1.

### Claim 20

(canceled)
